ArticleAntimicrobial agents and chemotherapy2011
OXA-163, an OXA-48-related class D β-lactamase with extended activity toward expanded-spectrum cephalosporins.
Article in Antimicrobial agents and chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 1 synthesis or guideline pooled it, 150 citations in OpenAlex.
- Structural basis for carbapenem-hydrolyzing mechanisms of carbapenemases conferring antibiotic resistance.International journal of molecular sciences · 2015Pooled it
- Diversity and function of OXA-48-like β-lactamase variants in environmentalApplied and environmental microbiology · 2026Article
- Hydrogen-Bonding Changes Cause Differences in Imipenem Breakdown Activity in OXA-48 Variants.Journal of chemical information and modeling · 2026Article
- Genomic landscape ofApplied and environmental microbiology · 2026Article
- Effect of Mutations on the Evolution of Extended Spectrum β-lactamases (ESBL).The protein journal · 2025Review
- Shifts inMicrobiology spectrum · 2025Article
- Diversity in the Common Fold: Structural Insights into Class D β-Lactamases from Gram-Negative Pathogens.Pathogens (Basel, Switzerland) · 2025Article
- Proteogenomic analysis demonstrates increasedAntimicrobial agents and chemotherapy · 2025Article
- Role of amino acid 159 in carbapenem and temocillin hydrolysis of OXA-933, a novel OXA-48 variant.Antimicrobial agents and chemotherapy · 2024Article
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaAnnals of clinical microbiology and antimicrobials · 2024Article
- First Report of OXA-181-ProducingMicrobiology spectrum · 2023Article
- Identification of a novel carbapenem-hydrolysing class D β-lactamase RAD-1 in Riemerella anatipestifer.The Journal of antimicrobial chemotherapy · 2023Article
- Structural and Biochemical Features of OXA-517: a Carbapenem and Expanded-Spectrum Cephalosporin Hydrolyzing OXA-48 Variant.Antimicrobial agents and chemotherapy · 2023Article
- Molecular typing methods & resistance mechanisms of MDRAIMS microbiology · 2023Review
- Genetic characteristics, antimicrobial susceptibility, and virulence genes distribution ofFrontiers in cellular and infection microbiology · 2023Article
- Molecular analysis of OXA-48-producing Escherichia coli in Switzerland from 2019 to 2020.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022Article
- OXA-48-Like β-Lactamases: Global Epidemiology, Treatment Options, and Development Pipeline.Antimicrobial agents and chemotherapy · 2022Review
- Multiscale Simulations Identify Origins of Differential Carbapenem Hydrolysis by the OXA-48 β-Lactamase.ACS catalysis · 2022Article
- Hospital outbreak of carbapenem-resistant Enterobacterales associated with aMicrobial genomics · 2022Article
- To Be or Not to Be an OXA-48 Carbapenemase.Microorganisms · 2022Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two bla(OXA-48)-like-positive isolates (Klebsiella pneumoniae and Enterobacter cloacae) were recovered in Argentina in 2008 as part of a large-scale survey focused on multidrug resistance in Enterobacteriaceae. In both cases, sequencing identified β-lactamase OXA-163, differing from OXA-48 by a single amino substitution and a 4-amino-acid deletion. OXA-163 hydrolyzed penicillins, ceftazidime, and cefotaxime, whereas OXA-48 did not. However, OXA-163 had a much lower ability to hydrolyze carbapenems than OXA-48, therefore barely being considered a carbapenemase. In both isolates, the bla(OXA-163) gene was located on plasmids that differed in structure and size. However, a detailed genetic analysis revealed a similar genetic context in those isolates, with the bla(OXA-163) gene being bracketed by novel transposase genes, making this genetic environment different from that reported for the bla(OXA-48) gene. This study identified the first class D β-lactamase compromising both extended-spectrum cephalosporin and carbapenem activities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.